Document is current
Any future updates will be listed below
-
Authors
Kanayama, Mayuko https://orcid.org/0000-0002-1947-6311
Colomba, Emeline
Shao, Yusra
Nielsen, Sarah M.
Esplin, Edward D. https://orcid.org/0000-0001-9205-3756
Lu, Changxue https://orcid.org/0000-0001-7565-8796
Isaacs, William B.
Henegan, John C.
Heath, Elisabeth I.
Luo, Jun https://orcid.org/0000-0002-1414-473X
Marlin, Régine https://orcid.org/0000-0001-7580-2997
Antonarakis, Emmanuel S. https://orcid.org/0000-0003-0031-9655
-
Funding
Funding for this research was provided by:
Patrick C Walsh Hereditary Prostate Cancer program
- License Information
-
More Information
Article History
Received: 9 April 2025
Revised: 4 June 2025
Accepted: 12 June 2025
First Online: 21 June 2025
Competing interests
: JL has served as a paid consultant/advisor for Sun Pharma, received research funding for his institution from Sanofi, Constellation, Calibr, AstraZeneca, and Cardiff Oncology, and is the lead inventor of AR-V7-related technologies owned by Johns Hopkins University and licensed to Qiagen and A&G. CL is the co-inventor of AR-V7-related technologies owned by JHU and licensed to Qiagen and A&G. SMN and EDE are employees of Labcorp (formerly Invitae Corp.). EDE is a scientific advisory board member and stockholder of Taproot Health, Exir Bio and ROMTech. WBI is a co-inventor on a patent (no. 9593380; Johns Hopkins Univ.) related to the discovery of HOXB13 as a prostate cancer susceptibility gene. WBI, MK, and JL are co-inventors on a patent (PCT/US2023/075775) filed by the Johns Hopkins University related to HOXB13 X285K as a biomarker and therapeutic target. ESA has served as a paid consultant/advisor for Sanofi, Dendreon, Janssen Biotech, ESSA, Merck, AstraZeneca, Clovis Oncology, Lilly, Bayer, and received an honorarium from Sanofi, Dendreon, Medivation, Janssen Biotech, ESSA, Astellas Pharma, Merck, AstraZeneca, Clovis Oncology. ESA received research funding from Janssen Biotech, Johnson & Johnson, Sanofi, Dendreon, Aragon Pharmaceuticals, Exelixis, Millennium, Genentech, Novartis, Astellas Pharma, Tokai Pharmaceuticals, Merck, AstraZeneca, Clovis Oncology, Constellation Pharmaceuticals, as well as travel accommodations from Sanofi, Dendreon, and Medivation. ESA is a co-inventor of a technology owned by Johns Hopkins University and licensed to Qiagen and A&G.
